AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002744
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002744
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002744
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002744
Drug: pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002744
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002744
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002744
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00327249
Drug: imexon
RxNorm normalized name: Imexon
DrugBank: Imexon (DB05003)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01947205
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01849861
Drug: Methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity
Trial: NCT01947205
Drug: suction curettage
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00762515
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush teeth two times daily for 6 weeks
Trial: NCT00762515
Drug: Triclosan
RxNorm normalized name: Triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush two times daily for 6 weeks
Trial: NCT00762515
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush two times daily for 6 weeks
Trial: NCT00834873
Drug: Carvedilol 25 mg tablets
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 25 mg
Trial: NCT01348503
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Escalating doses starting at 15 mg by mouth per day.
Trial: NCT01348503
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose of 400 mg by mouth twice a day.
Trial: NCT00700960
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
Trial: NCT01732224
Drug: Tenofovir + Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
Trial: NCT01732224
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
Trial: NCT00270634
Drug: Voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: voclosporin 0.4, 0.6, 0.8 mg/kg po BID
Trial: NCT00270634
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tacrolimus 0.05 mg/kg po BID
Trial: NCT00570635
Drug: XL820
RxNorm normalized name: XL820
DrugBank: XL820 (DB05146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XL820 capsules administered orally as a single agent at a dose of 800 mg daily
Trial: NCT00570635
Drug: XL820
RxNorm normalized name: XL820
DrugBank: XL820 (DB05146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
Trial: NCT00354835
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00354835
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01769898
Drug: Formoterol-budesonide
RxNorm normalized name: budesonide / formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
Trial: NCT04359212
Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
Trial: NCT03938389
Drug: Sacubitril-Valsartan Tab 97-103 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take Sacubitril-Valsartan for 26 weeks
Trial: NCT03938389
Drug: Valsartan 160mg
RxNorm normalized name: VALSARTAN 160MG CAP
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participant will take Valsartan for 26 weeks
Trial: NCT05327777
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigators provided set opioid prescriptions for 10 pills each patient.
Trial: NCT02055547
Drug: MK-8521 100μg
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
Trial: NCT02055547
Drug: MK-8521 200μg
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
Trial: NCT02172781
Drug: Ipratropium - unit dose vial
RxNorm normalized name: ipratropium Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02172781
Drug: Tiotropium - inhalation capsule
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172781
Drug: Placebo matching tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172781
Drug: Placebo matching ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01772238
Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference product
Trial: NCT01772238
Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product
Trial: NCT00852696
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
Trial: NCT02112123
Drug: Icariin
RxNorm normalized name: Icariin
DrugBank: Icariin (DB12052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00573313
Drug: S-adenosylmethionine
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
Trial: NCT00431041
Drug: solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00431041
Drug: oxybutynin immediate release
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02000388
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04143607
Drug: Placebo Gefitinib 250 mg
RxNorm normalized name: gefitinib 250 MG
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT04143607
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT00487435
Drug: Tapentadol (CG5503) Extended Release (ER)
RxNorm normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
Trial: NCT00609557
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
Trial: NCT00861276
Drug: Nasal Spray Nicotine Substitute (Experimental)
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
Trial: NCT00861276
Drug: Nasal Spray Nicotine Substitute (ad libitum)
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
Trial: NCT00150722
Drug: atorvastatin (or other tolerated statin + Niaspan/placebo)
RxNorm normalized name: Niaspan
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
Trial: NCT00860938
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
Trial: NCT01912807
Drug: Dextrose (D5NS)
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
Trial: NCT01912807
Drug: Ondansetron (Control)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
Trial: NCT01109043
Drug: Bisoprolol or bisoprolol + HCTZ
RxNorm normalized name: bisoprolol / hydrochlorothiazide
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
Trial: NCT00412464
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
Trial: NCT03232021
Drug: Pregabalin Oral Capsule [Lyrica] 75mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
Trial: NCT03232021
Drug: Pregabalin Oral Capsule [Lyrica] 150 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
Trial: NCT03483051
Drug: Potassium Nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
Trial: NCT03483051
Drug: Potassium Chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
Trial: NCT03856164
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
Trial: NCT01220622
Drug: Nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of nimodipine 30mg tid for 6 months
Trial: NCT00087529
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00922896
Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks
Trial: NCT00163319
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01853722
Drug: DCN01
RxNorm normalized name: Dexchlorpheniramine
DrugBank: Dexchlorpheniramine maleate (DB09555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three serial applications per periocular region.
Trial: NCT01853722
Drug: Unisol
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide (DB00180)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three serial applications per periocular region.
Trial: NCT00518986
Drug: armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/day
Trial: NCT02660502
Drug: Biochaperone insulin lispro 0.1 U/kg
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
Trial: NCT01972230
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02660502
Drug: Biochaperone insulin lispro 0.2 U/kg
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
Trial: NCT02660502
Drug: Biochaperone insulin lispro 0.4 U/kg
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
Trial: NCT02427919
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparison of the effect of G-CSF use
Trial: NCT03066427
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 50 mg/d
Trial: NCT01430442
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimegepant capsules
Trial: NCT01430442
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
Trial: NCT02977195
Drug: NP137 DL and RP2D
RxNorm normalized name: DL-Pantothenol
DrugBank: Panthenol (DB11204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT00494091
Drug: Temsirolimus (CCI-779)
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg/m2 IV TEMSR weekly (Japan, n=6)
Trial: NCT00494091
Drug: Temsirolimus (CCI-779)
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg IV TEMSR weekly (all other pts)
Trial: NCT03718143
Drug: Combination AZD1775 with AraC
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12
Trial: NCT01500161
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
Trial: NCT00699517
Drug: OMBRABULIN (AVE8062)
RxNorm normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. infusion followed by administration of cisplatin
Trial: NCT01500161
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
Trial: NCT01500161
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
Trial: NCT01500161
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
Trial: NCT00494897
Drug: Asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00494897
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00494897
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00919113
Drug: 2% sodium chondroitin sulfate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 20 mL Intravesical instillation
Trial: NCT02575651
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
Trial: NCT02722421
Drug: Levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
Trial: NCT02722421
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive efavirenz-based ART as part of standard of care
Trial: NCT00798603
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00798603
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01500161
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)